ArticleACS omega2025
Crystal Structure of Melphalan Hydrochloride and Its Association with Caffeine Improves Its Antineoplastic Action.
Article in ACS omega, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Melphalan hydrochloride (MEH) is a chemotherapy drug with antitumor activity, recognized for its classification as an alkylating agent. Over the past few decades, the drug has been administered to patients undergoing treatment for breast and ovarian cancers, and it is also intended for the treatment of multiple myeloma. It is commercially available in tablet and injection forms; however, its oral administration presents some limitations, including presystemic elimination and incomplete absorption. This study employs a simulated annealing approach and powder X-ray diffraction data to determine its crystal structure. The structure is confirmed by Rietveld refinement, which reveals good visual agreement between the generated model and experimental data. Given that MEH has low solubility in water, a screening conducted in the Mercury program (utilizing the CSD-Materials module) indicates the potential use of various molecular synthons to enhance the drug's efficacy. Grinding processes (manual and mechanochemical) are conducted with MEH and a coformer, caffeine (CAF), to form stoichiometric mixtures. The vibrational characteristics associated with MEH and CAF show low energy levels. The effects on cell viability of the MEH-CAF combination are studied at different concentrations and reveal more significant cytotoxicity against the HeLa cell line (cervical tumor) compared to healthy MRC-5 cells (human fetal lung fibroblasts).
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.